Joint Fat Pad Formulations for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for arthritis, such as osteoarthritis and rheumatoid arthritis, face limitations in providing sustained pain relief with minimal systemic side effects, as existing therapies often result in short-term pain reduction and long-term side effects, and local administration methods may not effectively target the joint tissues.
Innovation Solution
Development of sustained release formulations for administration to the joint fat pad, which include therapeutic agents like analgesics, anti-inflammatory agents, and immunosuppressive agents, allowing for localized delivery to the joint cavity and surrounding tissues, reducing systemic exposure and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral analgesics or corticosteroids are administered, then pain relief is provided, but systemic side effects such as gastrointestinal bleeding, renal toxicity, and addiction occur
Solution Approach 1:
The invention segments the drug delivery system by using biodegradable polymer microspheres that release the therapeutic agent locally at the injection site rather than systemically. This segmentation allows the drug to act where needed while avoiding exposure to other organs and tissues, thereby providing pain relief without systemic side effects.
Solution Approach 2:
The biodegradable polymer matrix serves as an intermediary carrier that holds and gradually releases the therapeutic agent. This intermediary system enables controlled local delivery, preventing the drug from entering the systemic circulation and causing harmful effects while maintaining therapeutic efficacy at the target site.
2Reliability
If localized corticosteroid injections are administered, then pain reduction is achieved, but cartilage breakdown and Cushing's syndrome occur after repeated injections
Solution Approach 1:
The invention employs a dynamic drug delivery system where the polymer matrix degrades over time, progressively releasing the therapeutic agent. This dynamic release mechanism maintains effective drug concentrations for extended periods without requiring repeated high-dose injections, thereby reducing cumulative side effects while sustaining pain relief.
Solution Approach 2:
The biodegradable polymer formulation provides continuous release of the therapeutic agent over an extended period (weeks to months), replacing the need for repeated bolus injections. This continuous action maintains therapeutic efficacy while minimizing the frequency of administrations and associated long-term side effects.
3Reliability
If repeated bolus injections are administered, then pain management is maintained, but the frequency of administration increases and side effects accumulate
Solution Approach 1:
The invention uses a pre-formulated biodegradable polymer matrix that is prepared in advance to provide sustained release. This preliminary preparation eliminates the need for frequent repeated injections, as a single administration provides prolonged pain management, thereby reducing the time loss associated with frequent medical visits and injections.
Solution Approach 2:
The invention changes the release parameter from immediate (bolus) to sustained (controlled release over weeks/months) by using biodegradable polymer matrices. This parameter change in drug release kinetics allows for extended pain management from a single administration, significantly reducing the frequency of required injections and associated time loss.
4Adaptability or versatility
If systemic administration is used, then therapeutic coverage is comprehensive, but the therapeutic index is reduced due to systemic exposure
Solution Approach 1:
The invention applies local quality by concentrating the therapeutic agent at the specific injection site and surrounding tissues rather than distributing it systemically. This localized high-concentration delivery provides comprehensive therapeutic coverage of the target area while minimizing exposure to other organs, thereby maintaining a high therapeutic index.
Data Source
AI summary
The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.